ReviewHormones (Athens, Greece)2026
Presentation of a missense MDH2 variant in a Greek patient with pheochromocytoma.
Review in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeApproximately 40% of pheochromocytomas and paragangliomas (PPGLs) are caused by germline mutations. MDH2 encodes the mitochondrial malate dehydrogenase, a Krebs cycle enzyme, which is essential for the conversion of malate to oxaloacetate and which has recently been added to the list of potential PPGL susceptibility genes. In this report, we present a MDH2 germline variant in a Greek patient with pheochromocytoma. CASE PRESENTATION: A 66-year-old male patient presented for investigation of a 5.4 cm right adrenal incidentaloma, with imaging features not indicative of adenoma. During hospitalization, he experienced daily episodes of paroxysmal hypertension, tachycardia, headache, and pallor lasting approximately 10-20 min. Hormonal evaluation revealed significantly increased 24-h urine metanephrine and normetanephrine levels, leading to a diagnosis of pheochromocytoma. After alpha-blockers preparation, an uncomplicated laparoscopic right adrenalectomy was performed. Histology revealed a pheochromocytoma (PASS score 7) with a Ki-67 index of 6%. Εxome sequencing identified the missense MDH2 variant, c.478G > A, resulting in replacement of valine by methionine at codon 160, p.Val160Met, of the MDH2 protein. Although this variant is considered to be of uncertain significance, recent in silico analysis showed that it results in protein three-dimensional structure destabilization and impairment of MDH2 molecular function, classifying it as likely pathogenic. Twelve months after adrenalectomy, the patient is asymptomatic with no evidence of disease recurrence.
conclusionsTo our knowledge, this is the second reported case with the germline c.478G > A MDH2 variant and a pheochromocytoma. Further genetic studies are needed to determine the role of this variant in the PPGLs pathogenesis.
Indexed as
Identifiers
41085877What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.